By Alberto Alerigi SAO PAULO (Reuters) -Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide ...

Hypera plans to introduce a generic version of semaglutide in Brazil following patent expiration in 2026. The company is optimistic about market growth despite potential price impacts. Analysts ...

US giant, Eli Lilly launched Mounjaro (tirzepatide) which is a prescription medicine for adults with type 2 diabetes used ...

March 23 marks Martyrs Day in India, commemorating the execution of Bhagat Singh, Sukhdev, and Rajguru in 1931. It also ...

Godrej Properties Ltd has purchased ~10 acres of land in Yelahanka, Bengaluru to develop ~1.5 million square feet of saleable ...

The Reserve Bank of India has accorded its approval on March 21, 2025 for acquisition of shareholding of up to 100% of the ...

Check stock performance, fundamentals, market cap, shareholding, financial reports, annual & quarterly results, and profit & loss statements.

Number 3: The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent ...